Table 1.
Patient characteristics
| Variable | Value (n=40) |
|---|---|
| Age at diagnosis (yr) | 60.5 (39-77) |
| CA-125 level at diagnosis (U/mL) | 1,846.5 (236.5-14,838.2) |
| CA-125 level before IDS (U/mL) | 24.4 (6.4-1,222.8) |
| FIGO stage | |
| IIIC | 15 (37.5) |
| IV | 25 (62.5) |
| Histologic subtype | |
| HGSC | 40 (100) |
| Method of IDS | |
| Laparotomy | 7 (17.5) |
| Laparotomy+HIPEC | 22 (55.0) |
| Laparoscopy | 3 (7.5) |
| Laparoscopy+HIPEC | 7 (17.5) |
| Not available | 1 (2.5) |
| Residual disease after IDS | |
| NGR | 20 (50.0) |
| ≤ 0.5 cm | 17 (42.5) |
| ≤ 1 cm | 1 (2.5) |
| ≤ 2 cm | 1 (2.5) |
| > 2 cm | 1 (2.5) |
| Not available | 1 (2.5) |
| Fagotti score | |
| 8 | 13 (32.5) |
| 10 | 18 (45.0) |
| 12 | 5 (12.5) |
| 14 | 2 (5.0) |
| Not available | 2 (5.0) |
| Response rate before IDSa) | |
| CR | 3 (7.5) |
| PR | 37 (92.5) |
| SD | 0 |
| PD | 0 |
| CRS | |
| 1 | 1 (2.5) |
| 2 | 28 (70.0) |
| 3 | 11 (27.5) |
| NAC regimen | |
| Paclitaxel+carboplatin | 40 (100) |
| No. of NAC cycles | |
| 3 | 38 (95.0) |
| 4 | 2 (5.0) |
Values are presented as median (range) or number (%). CA-125, cancer antigen-125; IDS, interval debulking surgery; FIGO, Federation of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; HIPEC, hyperthermic intraperitoneal chemo-therapy; NGR, no gross residual disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CRS, chemotherapy response score; NAC, neoadjuvant chemotherapy.
a)
According to the Response Evaluation Criteria in Solid Tumors [22].